Globus Medical (NYSE:GMED) Director Sells $2,176,000.00 in Stock

Globus Medical, Inc. (NYSE:GMED) Director Stephen Zarrilli sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the transaction, the director directly owned 25,000 shares in the company, valued at $2,176,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Globus Medical Stock Up 1.3%

Shares of Globus Medical stock opened at $86.81 on Friday. The stock has a market cap of $11.66 billion, a P/E ratio of 22.20, a P/E/G ratio of 1.38 and a beta of 0.95. Globus Medical, Inc. has a 12-month low of $54.15 and a 12-month high of $101.40. The business’s 50 day moving average is $80.58 and its 200-day moving average is $84.78.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. The business had revenue of $789.61 million during the quarter, compared to analysts’ expectations of $782.88 million. Globus Medical had a net margin of 17.02% and a return on equity of 14.57%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same period last year, the business earned $0.86 earnings per share. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, sell-side analysts expect that Globus Medical, Inc. will post 4.99 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on GMED. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Piper Sandler cut their target price on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research note on Monday, June 15th. Stifel Nicolaus reduced their price target on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a report on Wednesday, July 8th. Royal Bank Of Canada reduced their price target on Globus Medical from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, Wells Fargo & Company lowered their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating on the stock in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $101.77.

Hedge Funds Weigh In On Globus Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its stake in shares of Globus Medical by 45.9% during the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock worth $1,622,000 after buying an additional 7,086 shares during the last quarter. Integrated Wealth Concepts LLC grew its stake in Globus Medical by 33.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock valued at $320,000 after buying an additional 1,085 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Globus Medical by 38.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock valued at $2,228,000 after acquiring an additional 8,540 shares during the period. Jones Financial Companies Lllp raised its holdings in Globus Medical by 237.3% in the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after acquiring an additional 598 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Globus Medical by 8.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock worth $25,439,000 after acquiring an additional 28,027 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.